PMID- 31315325
OWN - NLM
STAT- MEDLINE
DCOM- 20190806
LR  - 20221207
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 66
IP  - 12
DP  - 2018 Dec
TI  - Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 
      Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral 
      Antidiabetic Drugs.
PG  - 46-49
AB  - AIM: To evaluate the efficacy of SGLT2 inhibitors as an add-on therapy along with 
      stricter lifestyle modification in Asian Indian type 2 diabetes mellitus (T2DM) 
      patients with inadequate glycemic control despite receiving an optimum dose of at 
      least 4 oral antidiabetic drugs (OADs). METHODOLOGY: A retrospective analysis of 
      data of 808 T2DM patients being treated with an SGLT2 inhibitor (Dapagliflozin, 
      Empagliflozin or Canagliflozin) as an add-on drug in patients with inadequate 
      glycemic control despite receiving optimum doses of at least any four 
      OADs(metformin, sulphonylureas, pioglitazone, DPP4 Inhibitors, alpha-Glucosidase 
      Inhibitors) and who preferred not to initiate insulin. RESULTS: The average age 
      of the patients included was 51.63 years (SD +/- 9.88). 57.7% were males. Average 
      weight was 81.95+/-16.08 kg. Mean duration of diabetes was 34.08+/-39.04 months. The 
      mean baseline fasting plasma glucose was 198.21 +/- 38.21 mg/dl and mean post 
      prandial plasma glucose was 264.22 +/- 45.22 mg/ dl. The baseline HbA1c was 8.92 +/- 
      1.47 %. Total 87.4 % of the cases responded to addition of SGLT2 inhibitors 
      during a mean follow-up period of 6 months. The fasting plasma glucose (FBS) was 
      reduced by -63.65 +/- 19.93 mg/dl to a mean FBS of 134.57 +/- 33.65 mg/dl (P=0.001). 
      The post prandial plasma glucose (PPBS) was reduced by -79.28 +/- 23.57 mg/dl to a 
      mean PPBS of 184.94 +/- 38.34 mg/dl (P=0.001). The mean HbA1c reduced significantly 
      by -1.63 +/- 0.99 % (P= 0.001). The mean weight reduction at 6 months of therapy 
      was -3.03+/- 01.84 kg that is 3.8 % decrease from baseline (p=0.001).The response 
      in age group < 55 years was 90.9 %, whereas in >/=55 years, it was 82.2% (p=0.001). 
      The males responded more (91.0%) compared to females (82.5%) (p=0.001). Those 
      with BMI < 23.5 kg/ m2 had marginally higher but insignificant response of 93.0% 
      as compared to 87.1% in patients with high a BMI (>/=23.5 kg/m2) (p=0.253). 
      Patients with < 5years duration of diabetes responded better (91.8%) as compared 
      to patients with a >/= 5 years of diabetes (85.4%). CONCLUSION: SGLT2 inhibitors 
      are effective in achieving desired glycemic goals even when used as a fifth 
      add-on drug along with strict lifestyle modification in patients with inadequate 
      glycemic control despite receiving an optimum dose of at least 4 oral 
      antidiabetic drugs (OADs). SGLT2 inhibitors can be effectively used at any stage 
      of diabetes.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Panikar, Vijay
AU  - Panikar V
AD  - Consultant, Department of Endocrinology, Lilavati Hospital and Research Centre, 
      Mumbai, Maharashtra.
FAU - Joshi, Shashank R
AU  - Joshi SR
AD  - Consultant, Department of Endocrinology, Lilavati Hospital and Research Centre, 
      Mumbai, Maharashtra.
FAU - Deogaonkar, Narayan
AU  - Deogaonkar N
AD  - Owner, Deogaonkar Hospital, Nashik, Maharahstra.
FAU - Vadgama, Jimit
AU  - Vadgama J
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, 
      Maharashtra,Corresponding Author.
FAU - Nasikkar, Nikhil
AU  - Nasikkar N
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, Maharashtra.
FAU - Kamat, Tejas
AU  - Kamat T
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, Maharashtra.
FAU - Sheikh, Saalim
AU  - Sheikh S
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, Maharashtra.
FAU - Jain, Chandni C
AU  - Jain CC
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, Maharashtra.
FAU - Wagle, Tejal
AU  - Wagle T
AD  - Resident, Lilavati Hospital and Research Centre, Mumbai, Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
MH  - Blood Glucose
MH  - Canagliflozin
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
EDAT- 2019/07/19 06:00
MHDA- 2019/08/07 06:00
CRDT- 2019/07/19 06:00
PHST- 2019/07/19 06:00 [entrez]
PHST- 2019/07/19 06:00 [pubmed]
PHST- 2019/08/07 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2018 Dec;66(12):46-49.